{
  "docId": "019de073-7087-77cd-a846-97dda09bac98",
  "docSlug": "031593eaf739f40f0f0c49214c912ed3",
  "documentTitle": "9 Meters Biopharma | Investor Presentation Deck | 30 slides",
  "authorId": "9-meters-biopharma",
  "authorName": "9 Meters Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 30,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "other",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The title uses an acrostic-style emphasis on letters (V, B, R, A, N) which spells VBRAN, likely a branding or mnemonic device.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de073-7087-77cd-a846-97dda09bac98/16",
  "deckHref": "/decks/019de073-7087-77cd-a846-97dda09bac98",
  "deckJsonHref": "/decks/019de073-7087-77cd-a846-97dda09bac98.json",
  "deckAnchorHref": "/decks/019de073-7087-77cd-a846-97dda09bac98#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.65,
        "x": 0.17,
        "y": 0.41
      },
      "kind": "callout",
      "text": "Primary study endpoint: Mean change from baseline in 24-hour total stool output (TSO) volume over the 6-week observation period",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b58bca00-fb54-4606-b93d-c637be19d925",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.8,
        "x": 0.14,
        "y": 0.58
      },
      "kind": "list",
      "text": "Study goals: Evaluate previous open-label trial efficacy in placebo-controlled and blinded setting; Confirm overall tolerability and safety profile; Identify go-forward dose and dosing interval for Phase 3 study design; Execute photo image diary for collection of intake and output; Gain experience with both patient and site interactions, patient dynamics, and SBS trial execution challenges to maximize opportunity for Phase 3 success",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "63eda463-3fd5-40b4-aa2b-5e6d2fe57445",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.14,
        "y": 0.23
      },
      "kind": "paragraph",
      "text": "Phase 2, double-blind, double-dummy, placebo-controlled multicenter study of the efficacy, safety and tolerability of vurolenatide in adult patients with short bowel syndrome (SBS)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6bf498d9-073b-477c-aa84-e21176cc3408",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.17,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "*Parenteral support not required for study entry and thus not available for all study patients.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "517a2f74-c6f8-47c2-b182-544215f86946",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.8,
        "x": 0.08,
        "y": 0.08
      },
      "kind": "title",
      "text": "Vurolenatide for short Bowel syndrome Regardless of pArenteral support requiremeNT",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "682c2279-5baf-43c2-9083-ada4e2604cf3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "3d25e606-2604-4fc4-b5d3-906f78fce5e9",
      "evidence": "Evaluate previous open-label trial efficacy in placebo-controlled and blinded setting; Confirm overall tolerability and safety profile; Identify go-forward dose and dosing interval for Phase 3",
      "confidence": 0.6
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}